title: [Endometrial adenocarcinoma appearing during tamoxifen therapy. Report of a clinical case].
abstract: Tamoxifen is a non-steroid estrogenic antagonist, used in post-surgical therapy of breast cancer. It interferes with endocrinous promotion of breast cancer. Tamoxifen could determine endometrial, even carcinomatous, alterations. The case of a postmenopausal patient surgically treated for breast cancer and successively treated with tamoxifen (20 mg/die), is reported. She underwent ultrasonographic and hysterosonographic endometrial evaluation and finally a hysterectomy with bilateral annessiectomy. This case seems to confirm tamoxifen possible carcinogenical effects on the endometrium.
authors: Dipartimento di Ginecologia ed Ostetricia, Ospedale S. Martino, Università degli Studi, Genova.
authors: M V
authors: MV
authors: Menada
authors: A
authors: A
authors: Corticelli
authors: A
authors: A
authors: Giannesi
authors: L
authors: L
authors: Nicoletti
authors: M
authors: M
authors: Podesta
authors: R
authors: R
authors: Rissone
authors: E
authors: E
authors: Fulcheri
mesh_terms: D000230:Adenocarcinoma / Q000139:chemically induced*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D016889:Endometrial Neoplasms / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008875:Middle Aged; D013629:Tamoxifen / Q000009:adverse effects*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen